Chemical Structure (Camptosar 01)
Camptosar Injection, Solution
Product Images NDC 0009-7529
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Camptosar (NDC 0009-7529). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Camptosar 02)
Figure 2 (Camptosar 03)
This appears to be a chart or graph depicting survival rates over time for a study involving Irinotecan and 5-FU/LV. The x-axis shows months and the y-axis represents survival probability. However, without more context or information it is difficult to interpret the chart accurately.*
Figure 3 (Camptosar 04)
Figure 4 (Camptosar 05)
This is a comparison study of Irinotecan and 5-FU in 127 and 129 individuals respectively. The median follow-up period was 15 months. However, due to the limited text, it is not clear what the numbers under "Median (mo)" represent. There is mention of a log-rank test and months, but no details are provided about what this means.*
Logo (Camptosar 06)
This is a description of a product called "Injectables". The product is distributed by a company named "Pharmacia & Upjohn Co", which is a division of "Pfizer Inc" located in NY, NY 10017.*
Principal Display Panel (100 mg/5 mL Vial Label)
This is a description of a medication called Camptosar® (irinotecan HCI injection) used for intravenous use only. It comes in a Cytosafe® vial, contains 100mg/5mL (20mg/mL) of a sterile, aqueous solution and should be stored at room temperature between 15°C to 30°C (59° to 86°F) while being protected from light and freezing. The packaging warns that it is a cytotoxic agent and advises to discard any unused portion. The dosage and use instructions can be found in the accompanying prescribing information. It is distributed by Pharmacia & Upjohn Co division of Pfizer Inc in New York, NY and was made in Australia. There is a lot and expiration date on the packaging as well.*
Principal Display Panel (100 mg/5 mL Vial Carton)
Camptosar® is an injectable medication for intravenous use only, containing irinotecan hydrochloride. It is a cytotoxic agent, used for cancer treatment, specifically, metastatic colorectal cancer. The dosage and use of Camptosar® must be determined according to the prescribing information. The medication should be stored at a controlled room temperature between 16°C to 30°C and protected from light, freezing, and damage or leakage in transit. The package is for a single-dose only and unused portions must be discarded, as per instructions.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
